ArticleHuman vaccines & immunotherapeutics2025
Seroprevalence of antibodies to hepatitis A, B and C viruses across all age groups in Chonburi Province, Thailand, 2022-2023.
Article in Human vaccines & immunotherapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viral hepatitis is a global challenge, particularly in low- and middle-income countries. The World Health Organization aims to eliminate HBV and HCV by 2030, targeting HBsAg prevalence below 0.1% in children under 5. This study analyzed sera from 1,459 participants of all ages in Chonburi province, Thailand, between October 2022 and January 2023 to assess whether this target has been met and to evaluate the seroprevalence of anti-HBs, anti-HBc, anti-hepatitis A virus (HAV), and anti-HCV in this population. Participants were healthy individuals with no immunosuppressed status. Results indicated a 0% HBsAg seroprevalence rate among children under 5, while those born before the universal immunization program had a seroprevalence rate of 5.6%. The lowest rate of anti-HBs seropositivity (anti-HBs ≥10 mIU/mL) was observed among adolescents aged 11-20 (31.7%). The anti-HBc seropositivity rate increased with age, following a pattern similar to HBsAg trends. Only a small percentage of subjects (0.3%) tested positive for anti-HCV. The seroprevalence of anti-HAV was below 20% in individuals under 40. These findings suggest that Thailand has met the regional HBsAg seroprevalence targets for children under 5 due to high HepB vaccination coverage and timely birth doses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.